29.93USD+0.37%Mkt Cap: 1.37B USDP/E: —Last update: 2026-06-01
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lea…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.37B USD
Enterprise Value1.08B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-166.31M USD
Revenue/Share—
Last Price29.93 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees77
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.71
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B4.23
EPS (TTM)-3.38
EPS (Forward)-3.48
52W Range
16.1086% of range32.14
52W High32.14 USD
52W Low16.10 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.13%
ROA-49.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-160.59M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-6.04%
Net Debt-325.96M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio13.95
Quick Ratio13.06
Book Value/Sh7.150 USD
Cash/Share7.008 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)41.94 USD
Target Range25.25 USD – 50.00 USD
# Analysts12
Ownership
Shares Out.46.57M
Float29.78M
Insiders2.77%
Institutions95.80%
Short Interest
Short Ratio17.2d
Short % Float16.69%
Short % Out.15.67%
Shares Short7.30M
Short (prev mo.)7.67M
Technical
SMA 5027.13 (+10.3%)
SMA 20022.53 (+32.9%)
Beta1.52
S&P 52W Chg27.94%
Avg Vol (30d)419.78K
Avg Vol (10d)411.39K
Technical Indicators
RSI (14)59.7
MACD-0.1002
MACD Signal-0.0431
MACD Hist.-0.0571
BB Upper30.93 USD
BB Middle28.37 USD
BB Lower25.81 USD
BB Width18.04%
ATR (14)1.602 USD
Vol Ratio (20d)1.90x